BACKGROUND: We examined risk of multiple myeloma (MM) associated with variants in genes involved in metabolism and response to exogenous chemicals [cytochrome P450 enzymes (CYP1B1, CYP2C9), epoxide hydrolase (EPHX1), paraoxonase 1 (PON1), arylhydrocarbon hydroxylase receptor (AHR), and NAD(P)H:quinone oxidoreductase (NQO1)]. METHODS: This study included 279 MM cases and 782 controls in a pooled analysis of two population-based case-control studies. One common variant from each candidate gene was genotyped using DNA from blood or buccal cells. We estimated risk of MM associated with each genotype, controlling for race, gender, study site, and age, using odds ratios (OR) and 95% confidence intervals (CI). RESULTS: Evaluations of the CYP1B1 V432L variant (rs1056836) suggested increased risk of MM among persons with the CG and GG genotypes compared to the CC genotype [OR (95% CI)=1.4 (1.0-2.0)]. Similar results were seen in analyses stratified by race and gender. We did not find any associations between MM and the CYP2C9, EPHX1, NQO1, or PON1 genes. CONCLUSIONS: CYP1B1 activates chemicals such as polycyclic aromatic hydrocarbons and dioxins to create oxidized, reactive intermediates, and higher gene activity has been shown for the G allele. We conducted the largest analysis to date on MM and these genetic variants and our results provide preliminary evidence that variation in CYP1B1 may influence susceptibility to MM.
BACKGROUND: We examined risk of multiple myeloma (MM) associated with variants in genes involved in metabolism and response to exogenous chemicals [cytochrome P450 enzymes (CYP1B1, CYP2C9), epoxide hydrolase (EPHX1), paraoxonase 1 (PON1), arylhydrocarbon hydroxylase receptor (AHR), and NAD(P)H:quinone oxidoreductase (NQO1)]. METHODS: This study included 279 MM cases and 782 controls in a pooled analysis of two population-based case-control studies. One common variant from each candidate gene was genotyped using DNA from blood or buccal cells. We estimated risk of MM associated with each genotype, controlling for race, gender, study site, and age, using odds ratios (OR) and 95% confidence intervals (CI). RESULTS: Evaluations of the CYP1B1 V432L variant (rs1056836) suggested increased risk of MM among persons with the CG and GG genotypes compared to the CC genotype [OR (95% CI)=1.4 (1.0-2.0)]. Similar results were seen in analyses stratified by race and gender. We did not find any associations between MM and the CYP2C9, EPHX1, NQO1, or PON1 genes. CONCLUSIONS:CYP1B1 activates chemicals such as polycyclic aromatic hydrocarbons and dioxins to create oxidized, reactive intermediates, and higher gene activity has been shown for the G allele. We conducted the largest analysis to date on MM and these genetic variants and our results provide preliminary evidence that variation in CYP1B1 may influence susceptibility to MM.
Authors: Lisa F Lincz; Ian Kerridge; Fiona E Scorgie; Michael Bailey; Arno Enno; Andrew Spencer Journal: Haematologica Date: 2004-05 Impact factor: 9.941
Authors: Bernice R Packer; Meredith Yeager; Brian Staats; Robert Welch; Andrew Crenshaw; Maureen Kiley; Andrew Eckert; Michael Beerman; Edward Miller; Andrew Bergen; Nathaniel Rothman; Robert Strausberg; Stephen J Chanock Journal: Nucleic Acids Res Date: 2004-01-01 Impact factor: 16.971
Authors: Dalsu Baris; Debra T Silverman; Linda Morris Brown; G Marie Swanson; Richard B Hayes; Ann G Schwartz; Jonathan M Liff; Janet B Schoenberg; Linda M Pottern; Raymond S Greenberg; Patricia A Stewart Journal: Scand J Work Environ Health Date: 2004-06 Impact factor: 5.024
Authors: Punam Pahwa; Helen H McDuffie; James A Dosman; Diane Robson; John R McLaughlin; John J Spinelli; Shirley Fincham Journal: J Occup Environ Med Date: 2003-08 Impact factor: 2.162
Authors: Deborah C Glass; Christopher N Gray; Damien J Jolley; Carl Gibbons; Malcolm R Sim; Lin Fritschi; Geoffrey G Adams; John A Bisby; Richard Manuell Journal: Epidemiology Date: 2003-09 Impact factor: 4.822
Authors: Won Jin Lee; Jane A Hoppin; Aaron Blair; Jay H Lubin; Mustafa Dosemeci; Dale P Sandler; Michael C R Alavanja Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897
Authors: Eric A Engels; Nilanjan Chatterjee; James R Cerhan; Scott Davis; Wendy Cozen; Richard K Severson; Denise Whitby; Joanne S Colt; Patricia Hartge Journal: Int J Cancer Date: 2004-08-10 Impact factor: 7.396
Authors: Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel Journal: PLoS One Date: 2013-04-18 Impact factor: 3.240